Quality of Life Validation in Laryngitis

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The primary purpose of this study was to establish the psychometric properties of a new disease specific Quality of Life questionnaire, the LPR-HRQL. The specific properties of the questionnaire that were evaluated were: validity, reliability, and responsiveness to change (as a measure of treatment effect).

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT05579587` - Transoral Incisionless Fundoplication (TIF) for Laryngopharyngeal Reflux (LPR) Patients
	Completed	`NCT01755221` - Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR

NCT number	NCT00641264
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 4
Start date	May 2001
Completion date	June 2003

Quality of Life Validation in Laryngitis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms